Zobrazeno 1 - 10
of 28
pro vyhledávání: '"van der Walt JS"'
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 19:1194-1196
Isoniazid preventive therapy is recommended in patients on antiretroviral treatment (ART) with latent tuberculous infection to prevent progression to active tuberculosis disease. Isoniazid (INH) inhibits cytochrome (CY) P3A4, which metabolises lopina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7e00c8802cbb58231ddc2b81d2296ff
https://doi.org/10.5588/ijtld.15.0044
https://doi.org/10.5588/ijtld.15.0044
The transfer and teaching of programming and programming related skills has become, increasingly difficult on an undergraduate level over the past years. This is partially due to the number of programming languages available as well as access to read
Autor:
Takahashi M; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan., Tokunaga E; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Mori J; Eli Lilly Japan K.K., Kobe, Japan., Tanizawa Y; Eli Lilly Japan K.K., Kobe, Japan., van der Walt JS; Eli Lilly and Company, Berkshire, UK., Kawaguchi T; Eli Lilly Japan K.K., Kobe, Japan., Goetz MP; Mayo Clinic, Rochester, MN, USA., Toi M; Breast Cancer Unit, Kyoto University Hospital, Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507, Japan. toi@kuhp.kyoto-u.ac.jp.
Publikováno v:
Breast cancer (Tokyo, Japan) [Breast Cancer] 2022 Jan; Vol. 29 (1), pp. 174-184. Date of Electronic Publication: 2021 Oct 18.
Autor:
Inoue K; Saitama Cancer Center, Saitama, Japan., Masuda N; National Hospital Organization, Osaka National Hospital, Osaka, Japan., Iwata H; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Takahashi M; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan., Ito Y; The Cancer Institute Hospital, Tokyo, Japan., Miyoshi Y; Hyogo College of Medicine, Hyogo, Japan., Nakayama T; Osaka International Cancer Institute, Osaka, Japan., Mukai H; National Cancer Center Hospital East, Kashiwa, Japan., van der Walt JS; Eli Lilly and Company, Surrey, UK., Mori J; Eli Lilly Japan K.K., Kobe, Japan., Sakaguchi S; Eli Lilly Japan K.K., Kobe, Japan., Kawaguchi T; Eli Lilly Japan K.K., Kobe, Japan., Tanizawa Y; Eli Lilly Japan K.K., Kobe, Japan., Llombart-Cussac A; Hospital Arnau de Vilanova, Valencia, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain., Sledge GW Jr; Stanford University School of Medicine, Stanford, CA, USA., Toi M; Breast Cancer Unit, Breast Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507, Japan. toi@kuhp.kyoto-u.ac.jp.
Publikováno v:
Breast cancer (Tokyo, Japan) [Breast Cancer] 2021 Sep; Vol. 28 (5), pp. 1038-1050. Date of Electronic Publication: 2021 Apr 01.
Autor:
Chigutsa E; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Kambhampati SRP; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Karen Sykes A; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Posada MM; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA., van der Walt JS; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA., Turner PK; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2020 Sep; Vol. 9 (9), pp. 523-533. Date of Electronic Publication: 2020 Aug 13.
Autor:
Kierzek AM; Certara QSP, Certara UK Limited, Sheffield, UK., Hickling TP; BioMedicine Design, Pfizer, Andover, Massachusetts, USA., Figueroa I; AbbVie Inc, North Chicago, Illinois, USA., Kalvass JC; AbbVie Inc, North Chicago, Illinois, USA., Nijsen M; AbbVie Inc, North Chicago, Illinois, USA., Mohan K; AbbVie Inc, North Chicago, Illinois, USA., Veldman GM; AbbVie Inc, North Chicago, Illinois, USA., Yamada A; Pharmacometrics JP, Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., Tokyo, Japan., Sayama H; Analysis & Pharmacokinetics Research Labs, Astellas Pharma Inc., Tsukuba-shi, Japan., Yokoo S; Analysis & Pharmacokinetics Research Labs, Astellas Pharma Inc., Tsukuba-shi, Japan., Gulati A; Pharmacometrics US, Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., Dhanikula RS; Bristol-Myers Squibb, Princeton, New Jersey, USA., Gokemeijer J; Bristol-Myers Squibb, Princeton, New Jersey, USA., Leil TA; Bristol-Myers Squibb, Princeton, New Jersey, USA., Thalhauser CJ; Bristol-Myers Squibb, Princeton, New Jersey, USA., Giorgi M; Certara QSP, Certara UK Limited, Sheffield, UK., Swat MJ; Certara QSP, Certara UK Limited, Sheffield, UK., Chelliah V; Certara QSP, Certara UK Limited, Canterbury, UK., Small BG; Certara QSP, Certara UK Limited, Sheffield, UK., Benson N; Certara QSP, Certara UK Limited, Canterbury, UK., Walker M; Certara QSP, Certara UK Limited, Sheffield, UK., Gadkar K; Development Sciences, Genentech, San Francisco, California, USA., Quarmby V; Development Sciences, Genentech, San Francisco, California, USA., Deng R; Development Sciences, Genentech, San Francisco, California, USA., Ferrante A; AME Biotechnology Discovery Research, Lilly Biotechnology Center, San Diego, California, USA., Dickinson GL; Eli Lilly and Company, Indianapolis, Indiana, USA., Van Der Walt JS; Eli Lilly Research & Development, Windlesham, UK., Zhou L; Eli Lilly and Company, Indianapolis, Indiana, USA., Chen X; BioMedicine Design, Pfizer, Cambridge, Massachusetts, USA., Jones HM; BioMedicine Design, Pfizer, Cambridge, Massachusetts, USA., Narula J; BioMedicine Design, Pfizer, Cambridge, Massachusetts, USA., Tourdot S; BioMedicine Design, Pfizer, Andover, Massachusetts, USA., Lavé T; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Ribba B; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., van der Graaf PH; Certara QSP, Certara UK Limited, Canterbury, UK.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2019 Nov; Vol. 8 (11), pp. 773-776. Date of Electronic Publication: 2019 Oct 08.
Autor:
Earp JC; US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD †Former Employee of AstraZeneca R&D Mölndal, Mölndal, Sweden ‡Novo Nordisc, Aalborg Øst, Denmark §Department of Biopharmaceutical Sciences, Uppsala University, Uppsala, Sweden ||Global Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe B.V., Leiden, The Netherlands., Mehrotra N, Peters KE, Fiorentino RP, Griebel D, Lee SC, Mulberg A, Röhss K, Sandström M, Taylor A, Tornøe CW, Wynn EL, Van der Walt JS, Garnett C
Publikováno v:
Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2017 Sep; Vol. 65 (3), pp. 272-277.
Autor:
Ross IL; Division of Endocrinology, Department of Medicine University of Cape Town, Cape Town, South Africa., Lacerda M; Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa., Pillay TS; Department of Chemical Pathology & NHLS Tshwane Academic Division, University of Pretoria, Pretoria, South Africa., Blom DJ; Division of Lipidology, Department of Medicine, University of Cape Town, South Africa., Johannsson G; Department of Endocrinology, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Dave JA; Division of Endocrinology, Department of Medicine University of Cape Town, Cape Town, South Africa., Levitt NS; Division of Endocrinology, Department of Medicine University of Cape Town, Cape Town, South Africa., Haarburger D; Ampath Laboratories Pomona, Gauteng Province, South Africa., van der Walt JS; Eli Lilly Windlesham, Surrey GU20 6PH, UK.
Publikováno v:
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme [Horm Metab Res] 2016 Dec; Vol. 48 (12), pp. 814-821. Date of Electronic Publication: 2016 Nov 03.
Autor:
Kredo T; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Tamara.kredo@mrc.ac.za.; Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa. Tamara.kredo@mrc.ac.za., Mauff K; Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa. katya.mauff@gmail.com., Workman L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. lesley.workman@uct.ac.za., Van der Walt JS; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. janstefan.vanderwalt@gmail.com., Wiesner L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. lubbe.wiesner@uct.ac.za., Smith PJ; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. peter.smith@uct.ac.za., Maartens G; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. gary.maartens@uct.ac.za., Cohen K; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. karen.cohen@uct.ac.za., Barnes KI; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. karen.barnes@uct.ac.za.; WorlldWide Antimalarial Resistance Network (WWARN), Oxford, UK. karen.barnes@uct.ac.za.
Publikováno v:
BMC infectious diseases [BMC Infect Dis] 2016 Jan 27; Vol. 16, pp. 30. Date of Electronic Publication: 2016 Jan 27.
Autor:
Gibbons JA; Medivation, Inc., 525 Market Street, 36th Floor, San Francisco, CA, 94105, USA. Jackie.Gibbons@medivation.com., de Vries M; Astellas Pharma Europe B.V., Leiden, The Netherlands., Krauwinkel W; Astellas Pharma Europe B.V., Leiden, The Netherlands., Ohtsu Y; Astellas Pharma Inc., Osaka, Japan., Noukens J; Kinesis Pharma B.V., Breda, The Netherlands., van der Walt JS; Astellas Pharma Europe B.V., Leiden, The Netherlands., Mol R; Astellas Pharma Europe B.V., Leiden, The Netherlands., Mordenti J; Medivation, Inc., 525 Market Street, 36th Floor, San Francisco, CA, 94105, USA., Ouatas T; Astellas Pharma Europe B.V., Leiden, The Netherlands.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2015 Oct; Vol. 54 (10), pp. 1057-69.